Targeting Neurogenic Inflammation to Combat Clostridioides difficile Infections

Background

Clostridioides difficile infection (CDI) is a prevalent gastrointestinal condition in developed countries, notably causing approximately half a million cases and 29,000 deaths annually in the United States alone. This infection arises from a disruption in the normal gut microbiota, where C. difficile, a spore-forming pathogen, exploits the weakened microbiome. The infection manifests with symptoms such as diarrhea and abdominal pain and can progress to severe conditions like pseudomembranous colitis and toxic megacolon. Current treatment approaches include antibiotics like vancomycin, fidaxomicin, or metronidazole, but they face significant challenges, including recurrent infections, antibiotic resistance, and hypervirulent strains. Furthermore, standard treatment can exacerbate inflammation in the colon, adversely impacting clinical outcomes. Thus, there is a critical need for more effective therapeutic options.

Technology Overview

This invention offers a novel approach to treating CDI by utilizing antagonists of neurogenic inflammation, specifically targeting neuropeptides such as substance P and calcitonin gene-related peptide (CGRP). By inhibiting these neuropeptides, the treatment mitigates the exaggerated inflammatory response induced by C. difficile toxins. Preliminary studies in mouse models have demonstrated promising results: direct application of C. difficile toxin B (TcdB) in mice causes rapid neurogenic inflammatory responses, while antagonists of substance P and CGRP significantly reduced these inflammatory markers. The studies show lower levels of immune cell infiltration and tissue damage after antagonist administration. Furthermore, blocking neuropeptide activities resulted in a quicker resolution of infection, reduced histopathological scores, and decreased pathogen colonization compared to controls. Importantly, these antagonists also prove effective against hypervirulent strains of C. difficile, offering a promising enhancement to current therapy practices.

Applications

• Treatment of active CDI in both hospitalized patients and those at high risk.
• Management of recurrent CDI cases to prevent subsequent infections.
• Use as an adjunct therapy alongside standard antibiotics to improve treatment outcomes.

Advantages

• Reduces inflammation effectively without direct antibiotic resistance concerns.
• Provides faster recovery and lowers the chance of infection recurrence.
• Effective against resistant and hypervirulent strains, expanding treatment success in challenging CDI cases.